Skip to main content
Find more clinical trials

Retinal Imaging for the Diagnosis of Cognitive Disorders and Dementia

Start: September 29, 2020
End: September 30, 2021
Enrollment: 100

What Is This Study About?

The nerve and blood vessel structures in the eye share similarities to the brain. This study will test the feasibility of a retinal image analysis system, EyeQuant, to detect changes in the nerves and blood vessels of the eye to diagnose mild cognitive impairment, Alzheimer's disease, and vascular dementia. Over one year, researchers will gather and compare eye images from participants with different cognitive conditions.

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: N/A

Must have:

  • Diagnosis of MCI, Alzheimer's disease, or vascular cognitive impairment and/or dementia
  • Able to attend study clinic visits on the assigned dates

Must NOT have:

  • Diagnosis of other medical conditions that could interfere with the study, such as conditions that affect the structure of the eyes or have symptoms similar to MCI, Alzheimers disease, or dementia
  • Patients who are pregnant or may become pregnant

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Mayo Clinic

Collaborator Sponsor

  • Eyenuk, Inc.
  • Malavika Bhaskaranand PhD
  • Kaushal Solanki

Source: ClinicalTrials.gov ID: NCT04567745